Biodexa Pharmaceuticals (STU:5MP2) Total Equity: €13.04 Mil (As of Dec. 2025)


STU:5MP2 Biodexa Pharmaceuticals PLC STU:5MP2
10 GF Score
Price €110,400.00
GF Value €95,593.41
View Full Analysis

What is Biodexa Pharmaceuticals Total Equity?

Biodexa Pharmaceuticals STU:5MP2 10 Total Equity is €13.04 Mil as of Dec. 2025. GuruFocus rates STU:5MP2 with a GF Score™ of 10/100 and a GF Value™ of €95,593.41.

Biodexa Pharmaceuticals's total equity for the quarter that ended in Dec. 2025 was €13.04 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Biodexa Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals Total Equity Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.30 3.64 5.43 10.05 13.04

Biodexa Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.43 10.32 10.05 13.45 13.04
STU:5MP2
10GF Score
Biodexa Pharmaceuticals PLC STU:5MP2
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodexa Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Biodexa Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=20.783-7.744
=13.04

Biodexa Pharmaceuticals's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=20.783-7.744
=13.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €13.04 Mil mean?
Biodexa Pharmaceuticals (STU:5MP2) has a Total Equity of €13.04 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Biodexa Pharmaceuticals and its competitors.
Is Biodexa Pharmaceuticals' Total Equity too high?
Biodexa Pharmaceuticals' current Total Equity is €13.04 Mil. Overall, Biodexa Pharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Total Equity compare to CASIF and OGEN?
Biodexa Pharmaceuticals' Total Equity of €13.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current Total Equity is €13.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (STU:5MP2) has a current Total Equity of €13.04 Mil. The stock's GF Value™ is €95,593.41, compared to a current price of €110,400.00 — trading 15.5% above its estimated fair value. The current Total Equity is €13.04 Mil. Biodexa Pharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Biodexa Pharmaceuticals (STU:5MP2), the current Total Equity is €13.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (STU:5MP2) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of €110,400.00 is trading 15.5% above its estimated GF Value™ of €95,593.41.

Key valuation signals for STU:5MP2:

  • Total Equity: €13.04 Mil
  • GF Value™: €95,593.41 vs. price of €110,400.00 (15.5% above fair value)
  • GF Score™: 10/100

No single metric tells the full story. See the STU:5MP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Other Exchanges BDRX:USA
Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
10GF Score

Get the complete analysis for STU:5MP2

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€110,400.00
Price
€95,593.41
GF Value